Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R. Vora A, et al. Among authors: rowntree c. Lancet Oncol. 2014 Jul;15(8):809-18. doi: 10.1016/S1470-2045(14)70243-8. Epub 2014 Jun 9. Lancet Oncol. 2014. PMID: 24924991 Clinical Trial.
Are survival and mortality rates associated with recruitment to clinical trials in teenage and young adult patients with acute lymphoblastic leukaemia? A retrospective observational analysis in England.
Hough R, Sandhu S, Khan M, Moran A, Feltbower R, Stiller C, Stevens MCG, Rowntree C, Vora A, McCabe MG. Hough R, et al. Among authors: rowntree c. BMJ Open. 2017 Oct 5;7(10):e017052. doi: 10.1136/bmjopen-2017-017052. BMJ Open. 2017. PMID: 28982824 Free PMC article.
Early morphological response is significantly associated with, but does not accurately predict, relapse in teenagers and young adults aged 10-24 years with acute lymphoblastic leukaemia (ALL): results from UKALL2003.
Furness CL, Kirkwood A, Rowntree C, Vora A, Mitchell C, Samarasinghe S, Goulden N, Moorman A, Hough R. Furness CL, et al. Among authors: rowntree c. Br J Haematol. 2019 Feb;184(4):663-666. doi: 10.1111/bjh.15150. Epub 2018 Feb 22. Br J Haematol. 2019. PMID: 29468646 Free article. Clinical Trial. No abstract available.
Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial.
Jackson RK, Liebich M, Berry P, Errington J, Liu J, Parker C, Moppett J, Samarasinghe S, Hough R, Rowntree C, Goulden NJ, Vora A, Kearns PR, Saha V, Hempel G, Irving JAE, Veal GJ. Jackson RK, et al. Among authors: rowntree c. Eur J Cancer. 2019 Oct;120:75-85. doi: 10.1016/j.ejca.2019.07.026. Epub 2019 Sep 6. Eur J Cancer. 2019. PMID: 31499383 Clinical Trial.
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, Enshaei A, Schwab C, Creasey T, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Marks DI, Fielding AK. Moorman AV, et al. Among authors: rowntree cj. Leukemia. 2022 Mar;36(3):625-636. doi: 10.1038/s41375-021-01448-2. Epub 2021 Oct 16. Leukemia. 2022. PMID: 34657128 Free PMC article. Clinical Trial.
83 results